Home › Funds › Sofinnova Investments, Inc. › IMNM
Sofinnova Investments, Inc. position in IMNM
IMMUNOME INC · Health Care
Sofinnova Investments, Inc. reported holding 1,720,316 shares of IMNM (IMMUNOME INC) in its Q2 2026 13F filing — a position valued at US$36.5M, representing 1.94% of its reported portfolio and ranking #18 among its reported holdings. Sofinnova Investments, Inc. has disclosed IMNM holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Sofinnova Investments, Inc.'s IMNM position evolved
Sofinnova Investments, Inc. first disclosed a stake in IMNM in Q1 2024 at 594,396 shares (US$14.7M). The position peaked in Q1 2026 at 1,701,904 shares, worth US$37.2M. Across 10 filings, Sofinnova Investments, Inc. increased the stake 7 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,720,316 shares valued at US$36.5M — an increase of 18,412 shares quarter over quarter.. Notable position changes include a 44% trim in Q3 2025 (shares rose 83% over the following quarter), a 271% increase in Q4 2025 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 594.40K | $14.67M | New |
| Q2 2024 | 655.68K | $7.93M | Add |
| Q3 2024 | 676.77K | $9.89M | Add |
| Q4 2024 | 746.82K | $7.93M | Add |
| Q1 2025 | 788.67K | $5.31M | Add |
| Q2 2025 | 778.48K | $7.24M | Reduce |
| Q3 2025 | 436.05K | $5.11M | Reduce |
| Q4 2025 | 1.62M | $34.76M | Add |
| Q1 2026 | 1.70M | $37.22M | Add |
| Q2 2026 | 1.72M | $36.45M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IMNM and 13F data
IMNM (IMMUNOME INC) is a Health Care company. 48 other funds we track also report a position in IMNM — the largest reported positions include Redmile Group, LLC (US$104.1M), Enavate Sciences GP, LLC (US$76.6M), SILVERARC CAPITAL MANAGEMENT, LLC (US$42.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IMNM
- Redmile Group, LLC 4.91M sh · $104.08M · Q2 2026
- Enavate Sciences GP, LLC 3.61M sh · $76.58M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 2.02M sh · $42.74M · Q2 2026
- READYSTATE ASSET MANAGEMENT LP 1.61M sh · $34.03M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 732.51K sh · $15.52M · Q2 2026
- NAN FUNG TRINITY (HK) Ltd 714.55K sh · $15.14M · Q2 2026
- Parkman Healthcare Partners LLC 594.20K sh · $12.59M · Q2 2026
- ALERUS FINANCIAL NA 383.42K sh · $8.12M · Q2 2026
- Atom Investors LP 297.49K sh · $6.30M · Q2 2026
More on Sofinnova Investments, Inc.
FAQ
How long has Sofinnova Investments, Inc. held IMNM?
Sofinnova Investments, Inc. has disclosed IMNM holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is Sofinnova Investments, Inc.'s current position in IMNM?
As of Q2 2026, Sofinnova Investments, Inc. holds 1.72M shares of IMNM (IMMUNOME INC), valued at $36.45M, representing 1.94% of its reported portfolio and ranking #18.
Has Sofinnova Investments, Inc. been buying or selling IMNM?
In the latest 13F filing (Q2 2026), Sofinnova Investments, Inc. increased its position in IMNM. The position peaked in Q1 2026 at 1.70M shares.
Which other funds hold IMNM?
Other major institutional holders of IMNM include Redmile Group, LLC, Enavate Sciences GP, LLC, SILVERARC CAPITAL MANAGEMENT, LLC, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.